Opinion: STAT+: The problem with potential changes to the biosimilar regulatory framework
STAT
SEPTEMBER 26, 2023
Biosimilars are no longer a new and untested class of medicines. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings.
Let's personalize your content